Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...
50 Tice Boulevard
Woodcliff Lake, NJ 07677
Founded in 2007
Eagle Pharmaceuticals Inc. Enters into Development and Licensing Agreement with Robert One, LLC
Aug 11 15
On August 5, 2015, Eagle Pharmaceuticals Inc. entered into Amendment No. 2 to Development and Licensing Agreement with Robert One, LLC to revise the Royalty Rate as defined in the Development and Licensing Agreement, dated as of February 13, 2009, as amended (the Robert Development and Licensing Agreement). The Second Amendment revises the definition of Royalty Rate to mean: (i) 50% with respect to a 505(b)(2) application; (ii) 30% with respect to an ANDA application; and (iii) 25% with respect to the Pemetrexed parenteral formulation.
Eagle Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 11 15
Eagle Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenue was $6,002,000 compared to $5,792,000 a year ago. The increase was driven by $1.4 million in net sales of Ryanodex, $600,000 in net sales of diclofenac/misoprostol and a $1.3 million increase in argatroban sales during the 2015 period, coupled with a $300,000 increase in royalty income, offset in part by the absence of license and other income. Loss from operations was $8,335,000 compared to $2,982,000 a year ago. Loss before income tax benefit was $8,330,000 compared to $2,934,000 a year ago. Net loss attributable to common stockholders was $8,177,000 compared to $2,934,000 a year ago. Loss per share attributable to common stockholders basic and diluted was $0.53 compared to $0.21 a year ago.
For the six months, the company's total revenue was $42,311,000 compared to $10,796,000 a year ago. Income from operations was $11,755,000 compared to loss from operations of $6,586,000 a year ago. Income before income tax benefit was $11,766,000 compared to loss before income tax benefit of $6,914,000 a year ago. Net income attributable to common stockholders was $11,520,000 compared to net loss attributable to common stockholders of $6,153,000 a year ago. Earnings per share attributable to common stockholders diluted were $0.73 compared to loss per share attributable to common stockholders diluted of $0.54 a year ago.
Eagle Pharmaceuticals Inc. Ratifies the Appointment of BDO USA, LLP as the Independent Registered Public Accounting Firm
Aug 10 15
Eagle Pharmaceuticals Inc. announced that at its AGM held on August 4, 2015, ratified the appointment of BDO USA, LLP as the independent registered public accounting firm of the Company for 2015.